XENE Xenon Pharmaceuticals Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Xenon Pharmaceuticals Inc. (XENE) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Full-year 2025 financial results announced Feb 26, 2026
• Complete figures in Exhibit 99.1 press release attachment

Item 7.01 · Regulation FD Disclosure

• Reg FD disclosure designating official investor communication channels: SEC filings, press releases, website, and social media
• Investors should monitor @XenonPharma (X/Twitter), LinkedIn, and Facebook for potentially material updates between formal filings

Other Xenon Pharmaceuticals Inc. 8-K Filings

Get deeper insights on Xenon Pharmaceuticals Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.